{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', '10.', 'REFERENCES', 'Aboud M, Orkin C, Podzamczer D, Bogner J, Baker D, Khuong-Josses M.-A., et al.', 'Durable suppression 2 years after switch to DTG+RPV 2-drug regimen: SWORD 1&2', 'studies. AIDS 2018. 23-27 July 2018. Amsterdam, Netherlands. Poster THPEB047.', 'Arribas JR, Girard PM, Landman R, et. al. Dual treatment with lopinavir-ritonavir plus', 'lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or', 'emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance', 'of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet', 'Infect Dis. 2015;15:785-92.', 'Arribas JR, Pialoux G, Gathe J, et. al. Simplification to coformulated elvitegravir,', 'cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease', 'inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV', '(STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority', 'trial. Lancet Infect Dis. 2014;14:581-89.', 'British HIV Association (BHIVA) guidelines for the treatment of HIV-1-positive adults', 'with antiretroviral therapy 2015 (2016 interim update). Available at:', 'http://www.bhiva.org/documents/Guidelines/Treatment/2016/treatment-guidelines-2016-', 'interim-update.pdf. Accessed February 8, 2017.', 'Cahn P, Madero JS, Arribas J, Antinori, Ortiz R, Clarke A, et al. Non-inferior efficacy of', 'dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine', '(TDF/FTC) fixed-dose combination in antiretroviral treatment-na\u00efve adults with HIV-1', 'infection - 48-week results from the GEMINI studies. AIDS 2018. 23-27 July 2018.', 'Amsterdam, Netherlands. Oral Abstract TUAB0106LB.', 'Cahn P, MJ Rolon, MI Figueroa et al. Dolutegravir-lamivudine as initial therapy in HIV-', '1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral', 'Design with Dolutegravir LamivudinE) study. Journal of the International AIDS Society.', '2017; 20 (1): 1-7.', 'Carr A, Hoy J, Pozniak A. The Ethics of Switch/Simplify in ART Trials: Non-Inferior or', 'Just Inferior? PLoS Med. 2012; 9(7): e1001240. doi:10.1371/journal.pmed.1001240', 'Available at:', 'http://journals.plos.org/plosmedicine/article/asset?id=info:doi/10.1371/journal.pmed.100', '1240.PDF. Accessed April 19, 2016.', 'CDC. Revised Surveillance Case Definition for HIV Infection - United States, 2014.', 'MMWR 2014; 63 (RR-03); 1 -10.', 'Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose', 'bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-', 'based regimens in virologically suppressed adults with HIV-1: 48 week results of a', 'randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018.', '80']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Department of Health and Human Services (DHHS). Guidelines for the use of', 'antiretroviral agents in HIV-1 infected adults and adolescents. May 2018. Available at:', 'https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0.', 'Accessed October 5, 2018.', 'Dolutegravir (TIVICAY) Product Insert. Available at:', 'http://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Inf', 'ormation/Tivicay/pdf/TIVICAY-PI-PIL.PDF. November 2017. Accessed January 16,', '2018.', 'EPIVIR/Lamivudine Product Insert. Available at:', 'https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_In', 'formation/Epivir/pdf/EPIVIR-PI-PIL.PDF. September 2017. Accessed January 16,', '2018.', 'Eron JJ, Benoit SL, Jemsek J, et. al. Treatment with Lamivudine, Zidovudine, or both in', 'HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter. N Engl J Med.', '1995;333:1662-69.', 'European AIDS Clinical Society (EACS) Guidelines for the clinical management and', 'treatment of HIV Infected Adults in Europe. Version 8.0, October 2017. Available at:', '  http://www.eacsociety.org/files/2015_eacsguidelines_8_0-english_rev-20160124.pdf.', 'Accessed February 8, 2017.', 'European Medicines Agency (EMA). Guidance on the Management of Clinical Trials', 'during the COVID-19 (Coronavirus) pandemic. Version 1 March 2020(a). Available at:', 'https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-', '10/guidanceclinicaltrials_covid19_en.pdf. Accessed April 16, 2020.', 'European Medicines Agency (EMA). Points to consider on implications of Coronavirus', 'disease (COVID-19) on methodological aspects of ongoing clinical trials. 25 March', '2020(b). Available at: https://www.ema.europa.eu/en/documents/scientific-', 'guideline/points-consider-implications-coronavirus-disease-covid-19-methodological-', 'aspects-ongoing-clinical_en.pdf. Accessed April 16, 2020.', 'Figueroa MI, Rolon MJ, Patterson P, et al. Dolutegravir-Lamivudine as initial therapy in', 'HIV-1 infected, ARV-naive patients: 96 week results of the PADDLE trial. Poster', 'presentation at the 9th IAS Conference on HIV Science; July 23-26, 2017; Paris, France.', 'Figueroa MI, Sued O, Patterson P, et al. Dolutegravir-Lamivudine as Initial Therapy in', 'HIV-infected, ARV Naive Patients: First Results of the PADDLE Trial. EACS 2015. 15th', 'European AIDS Conference. 21-24 October 2015. Barcelona, Spain. Abstract 1066.', 'Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York: John Wiley;', '1981.', 'Gallant, JE, Daar ES, Raffi F, et. al. Efficacy and safety of tenofovir alafenamide versus', 'tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine', '81']\n\n###\n\n", "completion": "END"}